Happiness Biotech Announces the Opening of its First Experience Store in Hainan, China, introducing the Company's 31st Experience Store

Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovative China-based nutraceutical and dietary supplements producer, announced today the opening of its first experience store in Hainan, China, which is the Company's 31^st experience store.

"Hainan is an important tourism attraction and an ideal travel destination for tourists in winter. With this first store, we gained access to the Hainan market," Mr. Wang Xuezhu, CEO of the Company, continued, "strategically, this is of great importance to the company in the tourism market, especially in winter."

"The experience store model is a unique model we developed mainly targeting the tourism market. In the experience stores, the tourists may learn the history and health benefits of Lucidum and listen to the lectures about our products. In past 3 years, we have established strategic relationship with most of the major travel agents in China.  As of March 31, 2019, the Company had a total of 25 experience stores across the country, including Wuyi Montain, Xiamen, Shanghai, Suzhou, Shenyang, Beihai and other major tourism attractions. We are excited to see that the total number of experience stores increased to 31 as of December 31, 2019, and we will continue to evaluate more tourism locations in China and potentially overseas in the near future." Mr. Wang commented.

About Happiness Biotech Group Limited.

Headquartered in Nanping, China, Happiness Biotech Group Limited is an innovative China-based nutraceutical and dietary supplements producer focused on the research, development, manufacturing and marketing of a variety of products made from Chinese herbal extracts and other ingredients. The Company's goal is to provide high-quality products to our consumers. Over the past 14 years, the Company has established a product portfolio consisting of 32 SFDA registered "Blue-Cap" SKUs of nutraceutical and dietary supplements products.

Forward-Looking Statements

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following:  the Company's goals and strategies; the Company's future business development; product and service demand and acceptance; changes in technology; economic conditions; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in China and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the Securities and Exchange Commission.  For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the reproduced articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.